dextromethorphan hydrobromide; guaifenesin; naproxen sodium
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM is an oral extended-release tablet combining dextromethorphan (cough suppressant), guaifenesin (expectorant), and naproxen sodium (NSAID analgesic/antipyretic). It is indicated for symptomatic relief of multiple cold and flu symptoms including cough, congestion, fever, and pain. The fixed-dose combination targets consumers seeking all-in-one OTC cold relief with extended dosing convenience.
Early-stage OTC launch with no existing competitive pressure indicates greenfield market positioning and need for aggressive commercial infrastructure build-out.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on MUCINEX 12HR COLD & FEVER offers exposure to OTC portfolio management, retail/pharmacy channel strategy, and consumer marketing in a well-established category with zero early competitive pressure. Career value lies in building brand equity during launch phase and executing efficient go-to-market strategy in a price-sensitive, high-volume segment.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo